Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

- - - 37,901

Total revenues 2,046,708 1,954,977 9,663,513 13,709,186

Operating expenses:

Research and

development 8,268,413 8,468,763 36,060,470 35,615,536

General and

administrative 2,820,543 3,372,108 13,569,578 12,254,892

Restructuring

charges 345,426 - 1,563,274 -

Total operating

expenses 11,434,382 11,840,871 51,193,322 47,870,428

Loss from operations (9,387,674) (9,885,894) (41,529,809) (34,161,242)

Interest income 661,381 898,786 2,971,666 3,394,751

Interest expense (57,631) (44,018) (209,885) (477,643)

Other income, net 5,949 1,124 7,108 6,873

Net loss $(8,777,975) $(9,030,002) $(38,760,920) $(31,237,261)

Basic and diluted

loss per share $(0.26) $(0.31) $(1.20) $(1.13)

Shares used in

computing basic and

diluted loss

per share 34,336,645 29,386,886 32,340,203 27,758,348


'/>"/>
SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 21, 2015 Cambridge Semantics, the leading provider ... announced that 2014 was a record-breaking year across the board ... the Anzo Smart Data Platform and our Smart Data solutions, ... from diverse data which led to record growth for the ...
(Date:1/22/2015)... California (PRWEB) January 22, 2015 Pipette.com ... Offer to their comprehensive portfolio of Eppendorf products. ... customers to purchase a Centrifuge 5424/5424 R and receive ... of either Eppendorf Research plus or Eppendorf Reference 2 ...
(Date:1/22/2015)... Geneva, Switzerland (PRWEB) January 22, 2015 ... for characterized mammalian Research Cell Banks (RCBs) used for ... generated Research Cell Banks will include Next-Generation Sequencing ... cell’s genetic architecture de-risks biologic manufacturing by ensuring the ...
(Date:1/22/2015)... Jan. 22. 2015  Varian Medical Systems (NYSE: VAR ... honored for its commitment to sustainability with inclusion on a ... the highest ranked healthcare equipment company among the Corporate Knights ... World Economic Forum at Davos, Switzerland . ...
Breaking Biology Technology:Cambridge Semantics Announces Record Results for 2014 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Varian Honored Among World's 100 Most Sustainable Corporations 2
... one of the largest provider of integrated and customized ... and investors that, on April 10, 2008, the National ... 264,000 m3 of,biodiesel, for delivery between July 1 and ... ensure supply of the necessary volumes for the,mandatory blend ...
... LAUSANNE, Switzerland, April 11 Galderma Pharma ... dermatology, today,announced that its U.S. holding company, ... CollaGenex Pharmaceuticals, Inc. (Nasdaq:,CGPI). As a result ... wholly owned,subsidiary of Galderma Laboratories., "We ...
... international start-up, CEOs, business development executives, and service providers ... ... the globe, MASSAPEQUA, N.Y. and CLEVELAND, April ... BioEnterprise Corporation, the Cleveland-based bioscience business,formation, recruitment, and acceleration initiative, ...
Cached Biology Technology:Galderma Completes Acquisition of CollaGenex 2Galderma Completes Acquisition of CollaGenex 3Galderma Completes Acquisition of CollaGenex 4IBF Conferences Inc*International Business Forum and BioEnterprise Corporation present the 2nd Annual Global Healthcare Investing Conference 2IBF Conferences Inc*International Business Forum and BioEnterprise Corporation present the 2nd Annual Global Healthcare Investing Conference 3
(Date:1/22/2015)...   EyeLock, Inc. , a market leader of iris-based identity ... to the new role of Senior Vice President of ... of mobile platforms and wearable solutions for EyeLock,s technologies. Gerber ... the semiconductor industry to his role at EyeLock, with expertise ...
(Date:12/24/2014)... , Dec. 23, 2014  Since its launch in December 2014, ... to eliminate the pain of trying to remember their usernames ... biometrics fused to their smartphones. To assist people who have ... the company that created 1U and focuses on redefining identity, ...
(Date:12/22/2014)... Research and Markets ( http://www.researchandmarkets.com/research/fx4bg3/the_global ) ... Global Watermarking and Fingerprinting Markets" report to ... This insight provides an overview ... markets. Watermarking aims to control and monitor piracy ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3The Global Watermarking and Fingerprinting Markets 2
... HONOLULU April 25, 2012 -- Many shark populations have ... excessive harvesting for their fins, as an incidental catch ... is particularly true for oceanic species. However, until now, a ... of Pacific reef sharks at a large geographic scale. ...
... disease normally found in subarctic climates has been identified for ... south as Herefordshire., Sclerotinia subarctica , a fungus known ... found in carrots and meadow buttercups in Perthshire by plant ... Life Sciences at the University of Warwick. , It is ...
... research sailboat gliding over glassy seas in the Pacific ... was littered with confetti-size pieces of plastic debris, until ... the particles disappeared. After taking samples of ... Proskurowski, a researcher at the University of Washington, discovered ...
Cached Biology News:Scientists provide first large-scale estimate of reef shark losses in the Pacific Ocean 2Wind pushes plastics deeper into oceans, driving trash estimates up 2Wind pushes plastics deeper into oceans, driving trash estimates up 3
... Reagent Grade C 19 H 9 Br ... PRODUCT SPECIFICATIONS Form: Powder Clarity of Solution: ... 3.0 - Yellow pH 4.6 - ... in agarose and acrylamide gel electrophoresis. Used ...
tracking dye in electrophoresis; free acid, C 19 H 10 BrO 5 S; MW: 669.96...
Denhardt's Solution is a mixture of blocking agents used in membrane-based hybridization protocols. The solution contains 1% Ficoll (type 400) 1% polyvinylpyrrolidone and 1% bovine serum albumin. Ste...
... ELF 97 Cytological Labeling Kit provides a ... detection of cellular targets, including cell-surface receptors ... Labeling Kit contains the patented ELF 97 ... yellow-green precipitate at the site of enzymatic ...
Biology Products: